

August 12, 2016

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of India
Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

**Scrip Code: NEULANLAB
Series: EQ**

Dear Sirs,

**Outcome of Board Meeting
Compliance with Regulation 33 of the SEBI Listing Regulations, 2015**

This is to inform you that the Board of Directors, at its meeting held on even date, had approved the Unaudited Financial Results for the quarter ended June 30, 2016. A copy of the same is enclosed.

This is for your information and records.

Yours faithfully,
For Neuland Laboratories Limited



**Sarada Bhamidipati
Company Secretary**

Encl: as above

NEULAND LABORATORIES LIMITED

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

(Amount in lakhs of ₹)

Sl. No.	Particulars	Quarter Ended 30.06.2016 (Unaudited)	Quarter Ended 31.03.2016 (Audited)	Quarter Ended 30.06.2015 (Unaudited)	Year Ended 31.03.2016 (Audited)
1	Income from operations				
	(a) Net Sales / Income from Operations	14,558.44	12,684.53	11,912.48	48,576.71
	(b) Other Operating Income	418.16	819.23	459.50	2,420.30
	Total Income from Operations (Net)	14,976.60	13,503.76	12,371.98	50,997.01
2	Expenses				
	(a) Cost of Materials consumed	6,970.72	6,577.83	6,700.39	25,956.67
	(b) Changes in inventories of finished goods and work-in-progress	79.14	(526.65)	(375.35)	(611.18)
	(c) Employee benefits expense	1,666.16	1,497.15	1,527.64	5,989.23
	(d) Depreciation and amortisation expense	436.07	411.16	380.20	1,574.26
	(e) Manufacturing expenses	1,462.10	1,608.90	1,225.70	5,284.20
	(f) Sales promotion expenses including sales commission	1,512.20	1,353.31	151.17	2,039.90
	(g) Other expenses	830.05	974.13	1,031.84	4,351.22
	Total expenses	12,956.44	11,895.83	10,641.59	44,584.30
3	Profit from operations before other income, finance costs and exceptional items (1-2)	2,020.16	1,607.93	1,730.39	6,412.71
4	Other Income	48.70	73.10	52.86	161.91
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	2,068.86	1,681.03	1,783.25	6,574.62
6	Finance Costs	609.68	523.29	654.10	2,446.60
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,459.18	1,157.74	1,129.15	4,128.02
8	Exceptional Items	-	-	-	-
9	Profit from ordinary activities before tax (7-8)	1,459.18	1,157.74	1,129.15	4,128.02
10	Tax expense	488.05	489.38	399.09	1,486.54
11	Net profit from ordinary activities after tax (9-10)	971.13	663.36	730.06	2,641.48
12	Extraordinary items	-	-	-	-
13	Net profit for the period (11-12)	971.13	663.36	730.06	2,641.48
14	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.39	895.39	895.39	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				17,437.92
16.i	Earnings per share (before extraordinary items) (of ₹10 each) (In absolute ₹)				
	(a) Basic (not annualized)	10.93	7.46	8.22	29.73
	(b) Diluted (not annualized)	10.93	7.46	8.22	29.73
16.ii	Earnings per share (after extraordinary items) (of ₹10 each) (In absolute ₹)				
	(a) Basic (not annualized)	10.93	7.46	8.22	29.73
	(b) Diluted (not annualized)	10.93	7.46	8.22	29.73
	See accompanying notes to the financial results				

NOTES:

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on August 11, 2016, and approved and taken on record at the Board of Directors meeting held on August 12, 2016.
- 2 EPS for quarters are not annualized.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- 4 The Company has entered into a Joint Development Agreement(JDA) with Phoenix Embassy techno Zone Private Limited for development of the land owned by the Company at Nanakramguda, Hyderabad. In terms of the said JDA, the Company would be entitled to receive approximately 23% share of the total saleable area of the proposed project, which would be duly determined on the basis of an approval of the building plans by the authorities concerned.
- 5 Previous period figures have been re-grouped/reclassified wherever necessary, to confirm to the current period's classification.

By Order of the Board
For Neuland Laboratories Limited



Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date: August 12, 2016